City of Norwalk signals intent to sue Purdue Pharma

City of Norwalk signals intent to sue Purdue Pharma

window._taboola = window._taboola || []; _taboola.push({ mode: ‘thumbnails-c’, container: ‘taboola-interstitial-gallery-thumbnails-5’, placement: ‘Interstitial Gallery Thumbnails 5’, target_type: ‘mix’ }); _taboola.push({flush: true}); window._taboola = window._taboola || []; _taboola.push({ mode: ‘thumbnails-c’, container: ‘taboola-interstitial-gallery-thumbnails-7’, placement: ‘Interstitial Gallery Thumbnails 7’, target_type: ‘mix’ }); _taboola.push({flush: true}); Photo: Erik Trautmann / Hearst Connecticut Media Norwalk Mayor Harry Rilling addresses a […]

Before Striking Outcome-Based Pharma Contracts, Payers Need Data

Before Striking Outcome-Based Pharma Contracts, Payers Need Data

If healthcare is to usher in the age of value-based care, health insurers are going to need plenty of data. Outcomes-based contracting is among the most significant paths to reach this new dynamic. The phrase refers to arrangements in which a pharma manufacturer is obligated to issue a refund or rebate to a payer, depending […]

Ultragenyx Pharma (RARE) Reports Filing, FDA Clearance of IND for DTX401, Gene Therapy for Treatment of …

Ultragenyx Pharma (RARE) Reports Filing, FDA Clearance of IND for DTX401, Gene Therapy for Treatment of …

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here. Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for DTX401, an adeno-associated […]

EU hits Indian drugmaker Theon Pharma with warning letter for falsifying records, other issues

EU hits Indian drugmaker Theon Pharma with warning letter for falsifying records, other issues

The European Medicines Agency issued a warning letter to Indian drugmaker Theon Pharmaceuticals, citing the company for falsifying records and inadequate quality control systems. The letter, posted on the EudraGMP website, said inspectors found one “critical” deficiency during an inspection conducted in early March. It was the first EMA inspection of the plant. The critical […]

Patent watch: Pharma looking to functional foods as part of the battle on cancer?

Patent watch: Pharma looking to functional foods as part of the battle on cancer?

The company, which specialises in cancer, also says the composition can be used in the treatment of cancer through pharmaceutical intervention. A patented protein complex known as HAMLET, derived from human breast milk, and related complexes like BAMLET derived from bovine alpha-lactalbumin, can kill more than 40 types of cancer cells from different origins and […]

Five things for pharma marketers to know: Monday, April 23, 2018

Five things for pharma marketers to know: Monday, April 23, 2018

Copyright © 2018 Haymarket Media, Inc. All Rights Reserved This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media’s Privacy Policy and Terms & Conditions. Source link

Pre-Market Technical Scan on Biotech Equities — Cara Therapeutics, Catabasis Pharma, Catalyst Biosciences, and …

Pre-Market Technical Scan on Biotech Equities — Cara Therapeutics, Catabasis Pharma, Catalyst Biosciences, and …

WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on CARA, CATB, CBIO, and CELG which can be accessed for free by signing up to www.wallstequities.com/registration. On Friday, April 20, 2018, US markets saw broad based losses with eight out of nine sectors finishing the trading sessions in […]

BRIEF-Proteostasis Therapeutics – Co & Astellas Pharma Entered Into Amendment No. 6 To Collaboration & License …

BRIEF-Proteostasis Therapeutics – Co & Astellas Pharma Entered Into Amendment No. 6 To Collaboration & License …

April 23 (Reuters) – Astellas Pharma Inc: * PROTEOSTASIS THERAPEUTICS – ON APRIL 20, CO & ASTELLAS PHARMA ENTERED INTO AMENDMENT NO. 6 TO COLLABORATION & LICENSE AGREEMENT DATED NOVEMBER 4, 2014 * PROTEOSTASIS THERAPEUTICS SAYS AMENDMENT EXTENDS RESEARCH TERM FOR INITIAL PROJECT UNDER ASTELLAS AGREEMENT TO DEC 4, 2018 – SEC FILING Source text: […]

Your Daily Pharma Scoop: Abeona's ABO-202, Revance Update, Ionis/Biogen's New Collaboration

Your Daily Pharma Scoop: Abeona's ABO-202, Revance Update, Ionis/Biogen's New Collaboration

Analysis focus: Abeona Therapeutics Today we will discuss Abeona Therapeutics (NASDAQ:ABEO), which is up more than 5% in early trading after announcing that the European Medicines Agency (NYSEMKT:EMA) has granted its gene therapy AB-202 an Orphan Drug designation for the treatment of neuronal ceroid lipofuscinos or Batten disease. This has been another solid year for […]

Biotech Analysis Central Pharma News: Biogen's Deal, Eli Lilly Partner Incyte Refile Baricitinib, Argos Loses Out

Biotech Analysis Central Pharma News: Biogen's Deal, Eli Lilly Partner Incyte Refile Baricitinib, Argos Loses Out

Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. Biogen Makes A Large Deal With Ionis For Neurological Disorder Treatments News: Recently, Biogen (BIIB) made a deal with Ionis Pharmaceuticals (IONS) to license out a host of treatments for neurological disorders. The […]